ESC
GILD icon

Eurizon SLJ Capital’s Gilead Sciences GILD Stock Holding History

Eurizon SLJ Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Hold
1,533
– – 0.07% 129
2026
Q1 		$214K Buy
+1,533
New +$215K 0.1% 116

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eurizon SLJ Capital's GILD Position: Q2 2026 in Review

Eurizon SLJ Capital held its Gilead Sciences (GILD) position steady in Q2 2026 at 1,533 shares worth $194K. The position accounts for 0.07% of the portfolio, ranked #129.

Eurizon SLJ Capital first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $214K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Eurizon SLJ Capital held 1,533 shares of Gilead Sciences worth $194K as of Q2 2026.
  • Eurizon SLJ Capital left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.07% of Eurizon SLJ Capital's portfolio in Q2 2026, its #129 holding.
  • Eurizon SLJ Capital first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Eurizon SLJ Capital's Gilead Sciences position peaked at $214K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Eurizon SLJ Capital's 13F filing for Q2 2026, filed 3 Aug 2026.